A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Since our founding in 2014, we have transformed from a research and development company to a fully-integrated commercial-stage organization with a diversified pipeline of product candidates. Our pipeline consists of small molecules designed to target cancer signaling pathways and address significant unmet needs in oncology and hematology. 2025 was a pivotal year for our company. On November 13, 2025, the FDA approved our new drug application, or NDA, for ziftomenib, which is being marketed in the United States under the trade name KOMZIFTITM, for the treatment of adults with relapsed or refractory acute myeloid leukemia, or AML, with a susceptible nucleophosmin 1, or NPM1, mutation who have no satisfactory alternative treatment options. KOMZIFTI is the first and only menin inhibitor approved by the FDA for once-daily oral administration.
| Metric | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | 0 | - | - | 0 |
| Net Income | -279M | -279M | -174M | -153M |
| EPS | $-3.18 | $-3.18 | $-2.02 | $-2.08 |
| Free Cash Flow | -71M | -71M | 134M | -125M |
| ROIC | -690.3% | -32.5% | -41.4% | -37.5% |
| Gross Margin | - | 0.0% | - | 0.0% |
| Debt/Equity | 0.06 | 0.06 | 0.03 | 0.02 |
| Dividends/Share | $0.00 | $0.00 | - | $0.00 |
| Operating Income | -304M | -304M | -193M | -166M |
| Operating Margin | 0.0% | 0.0% | - | 0.0% |
| ROE | -160.0% | -94.8% | -42.1% | -37.3% |
| Shares Outstanding | 88M | 88M | 86M | 73M |
| Metric | 2023 | |||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0 | N/A | N/A | 0 |
| Gross Margin | 0.0% | N/A | 0.0% | N/A |
| R&D | 115M | 170M | 251M | 251M |
| SG&A | 51M | 77M | 120M | 120M |
| EBIT | -166M | -193M | -304M | -304M |
| Op. Margin | 0.0% | N/A | 0.0% | 0.0% |
| Net Income | -153M | -174M | -279M | -279M |
| Net Margin | 0.0% | N/A | 0.0% | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||
| ROIC | -37.5% | -41.4% | -32.5% | N/M |
| ROE | -37.3% | -42.1% | -94.8% | -160.0% |
| ROA | -33.7% | -22.9% | -37.2% | -37.7% |
| Cash Flow | ||||
| Op. Cash Flow | -125M | 134M | -64M | -64M |
| Free Cash Flow | -125M | 134M | -71M | -71M |
| Owner Earnings | -155M | 100M | -102M | -102M |
| CapEx | 168K | 472K | 6.6M | 6.6M |
| Maint. CapEx | 2.5M | 848K | 1.0M | 1.0M |
| Growth CapEx | 0 | 0 | 5.6M | 5.6M |
| D&A | 2.5M | 848K | 1.0M | 1.0M |
| CapEx/OCF | N/A | 0.4% | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 28M | 34M | 37M | 37M |
| Debt Repayment | 7.3M | 0 | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | -438M | -715M | -658M | -139M |
| Cash & Equiv. | 37M | 224M | 149M | 149M |
| Long-Term Debt | 9.3M | 6.9M | 9.7M | 9.7M |
| Debt/Equity | 0.02 | 0.03 | 0.06 | 0.06 |
| Interest Coverage | -107.0 | -119.3 | -200.8 | -200.8 |
| Equity | 397M | 414M | 174M | 174M |
| Total Assets | 449M | 760M | 738M | 738M |
| Total Liabilities | 52M | 347M | 564M | 564M |
| Intangibles | 0 | N/A | 0 | 0 |
| Retained Earnings | -721M | -895M | -1.2B | -1.2B |
| Working Capital | 397M | 666M | 592M | 592M |
| Current Assets | 432M | 745M | 709M | 709M |
| Current Liabilities | 35M | 79M | 117M | 117M |
| Per Share Data | ||||
| EPS | -2.08 | -2.02 | -3.18 | -3.18 |
| Owner EPS | -2.12 | 1.16 | -1.17 | -1.17 |
| Book Value | 5.41 | 4.80 | 1.99 | 1.99 |
| Cash Flow/Share | -1.70 | 1.56 | -0.73 | -3.17 |
| Dividends/Share | 0.00 | N/A | 0.00 | 0.00 |
| Shares Out. | 73.4M | 86.1M | 87.6M | 87.6M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | -2.9 |
| P/FCF | N/A | 5.6 | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 1.8 | N/A | 4.6 |
| Price/Sales | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | 17.9% | N/A | -8.8% |
| Market Cap | 0 | 747M | 0 | 801M |
| Avg. Price | 0.00 | 18.71 | 0.00 | 9.14 |
| Year-End Price | 0.00 | 8.67 | 0.00 | 9.14 |
Kura Oncology, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 9.6x vs a median of 5.6x.
Kura Oncology, Inc. (KURA) has a 5-year average return on invested capital (ROIC) of -37.1%. This is below average and may indicate limited pricing power.
Kura Oncology, Inc. (KURA) has a market capitalization of $801M. It is classified as a small-cap stock.
Kura Oncology, Inc. (KURA) does not currently pay a regular dividend.
Kura Oncology, Inc. (KURA) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Kura Oncology, Inc. (KURA) generated $-71 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Kura Oncology, Inc. (KURA) has a debt-to-equity ratio of 0.06. This indicates a conservatively financed balance sheet.
Kura Oncology, Inc. (KURA) reported earnings per share (EPS) of $-3.18 in its most recent fiscal year.
Kura Oncology, Inc. (KURA) has a return on equity (ROE) of -94.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 3 years of financial data for Kura Oncology, Inc. (KURA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Kura Oncology, Inc. (KURA) has a book value per share of $1.99, based on its most recent annual SEC filing.